Dendritic cells (DCs) comprise two functionally distinct subsets: plasmacytoid DCs (pDCs) and myeloid DCs (mDCs). pDCs are specialized in rapid and massive secretion of type I interferon (IFN-I) in response to nucleic acids through Toll like receptor (TLR)-7 or TLR-9. In this report, we characterized a CD56 + DC population that express typical pDC markers including CD123 and BDCA2 but produce much less IFN-I comparing with pDCs. 
INTRODUCTION
Dendritic cells (DCs) are professional antigen-presenting cells found in virtually all tissues. The main function of DCs is to induce T-cell activation, polarization and expansion against invading pathogens while maintaining tolerance to self antigens (Steinman, 2007) . Three DC subsets have been identified in the human blood: plasmacytoid dendritic cell (pDC) and two subsets of myeloid DC (mDC) expressing CD1c (BDCA1) and CD141 (BDCA3) respectively (Dzionek et al., 2000; Ziegler-Heitbrock et al., 2010) . pDCs are characterized by their specific expression of CD123, BDCA2, BDCA4 and ILT7 (Dzionek et al., 2000; Cao et al., 2006; Rissoan et al., 2002) . In addition, pDCs express high levels of interferon regulatory factor 7 (IRF7), Toll like receptor (TLR)-7 and TLR-9. Accordingly, they produce large amounts of type I interferon (IFN-I) upon stimulation with nucleic-acid ligands of TLR7/TRL9 (Siegal et al., 1999; Cella et al., 1999) . Transcription factors E2-2 and Spi B are specifically expressed in pDCs and play important roles in their development and maintenance (Cisse et al., 2008; Schotte et al., 2004) .
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy characterized by the clonal proliferation of pDC-like cells (Facchetti et al., 2008) . Neoplastic cells from BPDCN patients express pDC specific molecules, such as BDCA2, CD123, CD4, TCL1, Bcl11A, CD2AP and Spi B (Petrella and Facchetti, 2010) . Additionally, BPDCN cells can produce IFN-I upon TLR7 and TLR9 ligands stimulation although at much lower level comparing with pDCs (Chaperot et al., 2001) . Interestingly, BPDCN cells also express CD56, which is not present on the majority of pDCs (Grouard et al., 1997) . A small population of DCs in normal or FLT3 mobilized human blood do express CD56, which have been proposed as a pDC subpopulation that gives rise to BPDCN (Petrella et al., 2002; .
In this report, we characterized these BDCA2 + CD123 + CD56 + DCs from human peripheral blood. Although they express some pDC featured molecules, the transcriptomic and functional characterizations indicate that they belong to mDCs rather than pDCs.
RESULTS

CD56
+ DCs are functionally distinct from pDCs BDCA2 and CD123 are commonly used for the identification of human pDCs in the blood and lymphoid tissues. A subpopulation of BDCA2 + CD123
DCs have been reported in human blood and proposed as a pDC subpopulation related to BPDCN (Petrella et al., 2002; (Fig. 3B , left panel) were present in the cDNA array data of human blood DC subsets (Robbins et al., 2008) . And the names of those differentially expressed genes are provided in Table S1 Fig. 3C and 3D ).
+ DCs are functionally analogous to mDCs TLR expression patterns of pDCs and mDCs are drastically different. pDCs preferentially express TLR7 and TLR9 while mDCs express higher levels of TLR2 and TLR4 (Liu 2005; Cerboni et al., 2013) . We found that the expression level of TLR4 (Fig. 4A ) and the amount of TNFα produced upon LPS stimulation (Fig. 4B and 4C) were similar between CD56 + DCs and mDCs. Moreover, CD56 + DCs could produce IL-12 at a comparable level to mDCs at both RNA ( Fig. 4D ) and protein level (Fig. 4E ). While pDCs did not produce IL-12 ( Fig. 4D and 4E) as previously reported (Kadowaki et al., 2001) . Different from pDCs, mDCs could prompt T-cell proliferation without prior stimulation or activation. In order to further characterize the relationship between CD56 + DCs, pDCs and mDCs, we examined more gene expression that related to antigen presentation. MHC II molecules and CD86
were highly expressed on CD56 + DCs compared to pDCs at RNA level (Table S3 ). These were confirmed at protein level by FACS analysis ( ) and we found that GILT and cathepsins were expressed at much higher levels in CD56 + DCs than pDCs (Table S3) . We next examined the antigen presentation by CD56 + DCs, pDCs and mDCs. Allogeneic naïve T cells were co-cultured with purified DCs and analyzed by tritium incorporation. The CD56 + DCs stimulated comparable T-cell proliferation to mDCs, while pDCs did not induce significant T-cell expansion (Fig. 4G) . (Fig. 1B) . In order to further characterize the relationship between CD56 + DCs and pDCs, we examined more pDC-specific genes at both RNA and protein levels in other DC subsets. And we found that BDCA4 and ILT7, two additional pDC specific surface markers, were expressed on CD56 + DCs but not mDCs (Fig. 5A ). Both E2-2 and SpiB, the two important transcription factors for pDC lineage development, were expressed in CD56 + DCs at slightly lower levels than pDCs in the RNAseq data (Table S4 ) and confirmed by RT-PCR (Fig. 5B , left two panels). It is worth to pointing out that the expression levels of E2-2 and SpiB in CD56 + DCs were much higher than in mDCs (Fig. 5B , left two panels). In addition, pDC highly expressed genes IRF7, BCL11A and CD2AP (Marafioti et al., 2008) were also expressed in CD56 + DCs at a slightly lower level compared to pDCs (Table S4) . However, other pDC specific genes, such as Granzyme B, TCL1A (Herling et al., 2003) , PACSIN1 (Esashi et al., 2012) and BAD-LAMP (Defays et al., 2011) , were expressed at least 10 times higher in pDCs than in CD56 + DCs in RNAseq data (Table S4) In a previous report, we have found that BPDCN shows both myeloid and pDC characteristics (Cerboni et al., 2013) . In order to clarify the relationship among BPDCN, pDC and CD56 + DCs, we analyzed the differentially expressed genes between BPDCN and pDCs. We identified 127 genes express at higher levels in BPDCN than in pDC in cDNA array data (Fig. 6A , left panel; Table S7 ), but 93 (73%) of them are highly expressed in CD56 + DCs compared to pDCs in our RNA-seq data (Fig. 6A, right panel) . Similarly, there are 1143 genes expressed at lower levels in BPDCN cells than in pDCs (Fig. 6B , left panel; (Chaperot et al., 2001; Adachi et al., 1994; Brody 1995; Uchiyama 1998; Petrella et al., 1999) and was named as blastic plasmacytoid dendritic cell neoplasm (BPDCN) (Facchetti et al., 2008) . Here in this report, we characterized a BDCA2 + CD123 + CD56 + blood DC subset, which has been considered as a subpopulation of pDCs (Petrella et al., 2002) . We demonstrated that the CD56 + DCs clustered with mDCs by transcriptional profiling at whole genome level. Accordingly, CD56 + DCs responded to TLR4 stimulation and prime naïve T cells without prior stimulation. And this agrees with our previous finding that BPDCN are characterized by their mixed pDC and myeloid signature (Sapienza et al., 2014) . However, CD56 + DCs are distinguished from other 
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mDCs by expressing pDC specific molecules. Thus, we propose that CD56 + DCs represent a unique mDC subset and their function in immune response warrant further characterization. Besides BPDCN, another pDC related tumoral condition, pDC proliferations in patients with myeloid disorders (PPMD), has also been reported (Petrella and Facchetti 2010 . However, CD56 expression, which is the hallmark of BPDCN, is not detected in PPDM (Petrella and Facchetti 2010; Vermi et al., 2004) . Granzyme B (GrB) expresses at high level in pDCs (Rissoan et al., 2002) and is also positive in PPMD (Vermi et al., 2004) . However, most reported BPDCN cases are GrB negative (Chaperot et al., 2001; Petrella et al., 2002; Pilichowska et al., 2007; An et al., 2013) . Here in this study, we show CD56 + DCs express much lower level of GrB compared to pDC (Table S4) . We speculate that PPMD may be the tumor counterpart of pDC, while BPDCN may represent the counterpart of CD123 + CD56 + DCs. This hypothesis needs to be further investigated in the future by transcription profiling at whole genome level for both DC subsets and their tumor counterparts. It is worth pointing out that the human CD123 + CD56 + DCs are similar to a CX 3 CR1 + CD8α + mouse DC subset, which also exhibits mixed characteristics of pDC and mDC (Ghosh et al., 2010 And we propose that BPDCN should be classified as mDC but not pDC related leukemia. Table S5 .
MATERIALS AND METHODS
FACS analysis of DC subsets in human blood
DC enrichment and in vitro stimulation
DCs were enriched by lineage (CD3, CD14, CD16, CD19) depletion, then lineage negative cells (2 × 10 5 in 200 μL culture medium) were stimulated with TLR ligands or viruses for 4 h followed by another 2 h in the presence of Golgi Blocker (BD Biosciences, Franklin Lakes, NJ, USA). Cells were stained with surface markers and permeablized and stained with antibodies against various cytokines. TLR ligands were purchased from Invivogen (San Diego, CA, USA) and used at following concentrations: LPS (1 μg/mL), CpG 2216 (2 μg/mL), R848 (2 μg/mL). Heat inactivated influenza virus A/PR8/34 was used at 10 MOI for stimulation.
DC purification and stimulation
The lineage (CD3, CD14, CD16, CD19, CD20) depleted PBMC were stained with HLA-DR (APC-Cy7), CD2 (PE-Cy7), CD11c (APC), CD56 (PerCP-cy5.5) and CD123 (BV421 
RNA-seq and data analysis
RNA extraction and sequencing were done by BGI Tech (Shenzhen, Guangdong, China). The gene expression level was measured by the number of uniquely mapped reads per kilobase of exon region per million mappable reads (RPKM). The RNA-seq raw data was aligned to the reference genome (hg19) (Trapnell et al., 2009) . The gene expressions of other cell types used in our study were obtained from cDNA array data by Scott H Robbins (Robbins et al., 2008 (Eisen et al., 1998) and principal component analysis (PCA) (Alter et al., 2000) . Detailed methods of RNA-seq and data analysis were provided in the supplemental file. BPDCN microarray data of 6 cryopreserved tissue samples (Sapienza et al., 2014) by Affymetrix microarray platform were normalized with the rank invariant method using Lumi (Bioconductor) (Du et al., 2008) . Statistics for differential expression were applied by Limma (Bioconductor), (Smyth 2004 ) and we defined BPDCN significant differential expressed genes on normalized data as adjusted P-value less than 0.05. One hundred and twenty seven BPDCN highly expressed genes and 1143 BPDCN lowly expressed genes were matched to our RNA-seq datasets of pDC and CD56 + DCs
(genes with RPKM less than 10 were deleted). Heat maps were displayed using the R software.
RT-PCR
RNA was extracted from purified DCs and reverse transcribed with Oligo dT primers. Quantitative real time PCR (RT-PCR) was performed using cDNA with EF1α gene as internal control. Primers for RT-PCR are listed in Table S6 .
T-cell proliferation assay 
